BioLineRx Balance Sheet Health
Financial Health criteria checks 5/6
BioLineRx has a total shareholder equity of $13.1M and total debt of $9.6M, which brings its debt-to-equity ratio to 73.6%. Its total assets and total liabilities are $51.6M and $38.5M respectively.
Key information
73.6%
Debt to equity ratio
US$9.62m
Debt
Interest coverage ratio | n/a |
Cash | US$28.17m |
Equity | US$13.06m |
Total liabilities | US$38.54m |
Total assets | US$51.60m |
Recent financial health updates
Recent updates
Financial Position Analysis
Short Term Liabilities: YP2A's short term assets ($35.7M) exceed its short term liabilities ($23.9M).
Long Term Liabilities: YP2A's short term assets ($35.7M) exceed its long term liabilities ($14.7M).
Debt to Equity History and Analysis
Debt Level: YP2A has more cash than its total debt.
Reducing Debt: YP2A's debt to equity ratio has increased from 19.3% to 73.6% over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: YP2A has sufficient cash runway for 12 months based on last reported free cash flow, but has since raised additional capital.
Forecast Cash Runway: YP2A is forecast to have sufficient cash runway for 11 months based on free cash flow estimates, but has since raised additional capital.